Compositions of midodrine and methods of using the same
AssigneeXenamed Corp.
InventorsYogesh DANDIKER, Maulik PANCHAL, Xiao YU
Life of this patent
Estimating the term…
Abstract
This disclosure provides pharmaceutical compositions comprising midodrine, a pharmaceutically acceptable salt thereof, desglymidodrine, a pharmaceutically acceptable salt thereof, or a combination therefore that can be administered to a human subject in need thereof in a supine position. The disclosure also provides pharmaceutical compositions which can be administered once-a-day. This disclosure further provides pharmaceutical compositions comprising an extended release composition and providing a delayed release period between about 30 min to about 12 hours.
Claims21
1-76. (canceled)
A method of treating a subject in need thereof, comprising administering to the subject a composition comprising:
- (a) a delayed release composition comprising a delayed release agent;
- and
- (b) an extended release composition comprising (i) an effective amount of an active agent selected from midodrine, a pharmaceutically acceptable salt of midodrine, desglymidodrine, a pharmaceutically acceptable salt of desglymidodrine, or a combination thereof, and (ii) a rate controlling agent;
- wherein the subject has a disorder selected from the group consisting of:
- orthostatic hypertension;
- postural orthostatic tachycardia syndrome (POTS);
- dysautonomia;
- symptoms of chronic orthostatic hypotension corresponding to autonomic failure associated with Bradbury-Eggleston syndrome, Shy-Drager syndrome, diabetes mellitus disease, and Parkinson's disease;
- and retrograde ejaculation.
A method of treating postural orthostatic tachycardia syndrome (POTS) in a subject in need thereof, comprising administering to the subject a single dose of a composition comprising an effective amount of an active agent selected from midodrine, a pharmaceutically acceptable salt of midodrine, desglymidodrine, or a pharmaceutically acceptable salt of desglymidodrine,
- wherein release of the active agent is delayed for about 1 hour to about 12 hours.
Dependencies are inferred from the claim text.